#USA #San Francisco #Microbiome Science #Pendulum Therapeutics #Amy Errett

Pendulum Therapeutics Welcomes Amy Errett to Board of Directors

Pendulum Therapeutics, a prominent player in the field of microbiome science, declared its commitment to expanding its leadership team by appointing Amy Errett, the founder and CEO of Madison Reed, to its Board of Directors. This strategic move comes amidst increasing consumer awareness regarding the significance of microbiome health.

In her new role, Errett will leverage her extensive experience as an entrepreneur and consumer brand expert to aid Pendulum in navigating its next growth phase. With the focus of Pendulum Therapeutics predominantly on delivering clinically validated microbiome products, Errett's reputation for building impactful consumer brands is expected to enhance the organization’s reach within the public health space. Her involvement highlights a crucial timing for Pendulum, which is currently witnessing a surge in demand for its innovative products aimed at not just gut health, but also metabolic and women’s health.

Errett's entrepreneurial journey began with the establishment of Madison Reed, where she set forth with a mission to revolutionize the hair color industry by emphasizing innovation, accessibility, and a remarkable customer experience. Under her stewardship, Madison Reed has emerged as a leading direct-to-consumer beauty brand in the United States, engaging millions of consumers through a multi-faceted business model. Her earlier career included being a General Partner at Maveron, a venture capital firm co-founded by former Starbucks CEO Howard Schultz, and serving in a key role at E*TRADE.

Colleen Cutcliffe, Co-Founder and CEO of Pendulum Therapeutics, expressed enthusiasm about Errett's appointment, emphasizing the extraordinary record she holds in building consumer brands that challenge traditional norms and effectuate significant changes. With their goal to make groundbreaking microbiome science more accessible, Errett’s experience in consumer engagement and innovative strategy is expected to be invaluable.

Errett herself stated her admiration for Pendulum’s groundbreaking work, stressing the importance of microbiome health. She underscored Pendulum’s commitment to scientific rigor and transformative innovation, which drew her toward this opportunity. Her board position signifies her belief in Pendulum’s potential to reshape health perspectives through microbiome science.

Alongside noted investments and a decade of research, Pendulum Therapeutics has made strides with significant breakthroughs in microbiome science. They launched Pendulum Glucose Control, recognized as the first clinically proven probiotic to reduce A1C levels in individuals with Type 2 diabetes. Moreover, they pioneered the use of the live strain Akkermansia muciniphila, known for its role in strengthening gut lining and enhancing metabolic balance.

More recently, Pendulum introduced Gut Fuel, an innovative fiber powder crafted to nourish gut microbiomes. This product successfully combines various resistant starches, diverse plant fibers, and polyphenols, promoting beneficial gut bacteria without demanding dietary changes from users.

Pendulum's commitment to expanding the knowledge and applications of microbiome science indicates their ambition to establish new pathways in preventive healthcare and therapeutic solutions. The alignment of Errett's consumer insight with Pendulum's scientific background could spell a new era of growth and innovation in health and wellness for consumers.

As Pendulum continues to extend its product offerings and capitalize on the growing interest in microbiome science, Errett’s role on the board is anticipated to significantly contribute to achieving the company’s mission—a mission that is carried forward not only through rigorous R&D but also through effective consumer engagement and education.

With an increasing focus on the microbiome as a key component of health, Pendulum Therapeutics stands poised to lead the charge in transforming consumer health experiences through its cutting-edge innovations and strategic leadership.